Pyrosequencing Dried Blood Spots Reveals Differences in HIV Drug Resistance between Treatment Naïve and Experienced Patients

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Ji, Hezhao ^a   Li, Yang ^a   Liang, Binhua ^a,b   Pilon, Richard ^a   MacPherson, Paul ^c   Bergeron, Michèle ^a   Kim, John ^a   Graham, Morag ^a,b   Van Domselaar, Gary ^a   Sandstrom, Paul ^a   Brooks, James ^a  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; LOPINAVIR PLUS RITONAVIR; RITONAVIR;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRIED BLOOD SPOT TESTING; DRUG EXPOSURE; DRUG INTERMITTENT THERAPY; GENOTYPING TECHNIQUE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTERMETHOD COMPARISON; NONHUMAN; PATIENT MONITORING; PROGNOSIS; PYROSEQUENCING; VIRUS LOAD; VIRUS TYPING;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; DRIED BLOOD SPOT TESTING; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPING TECHNIQUES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PLASMA; SEQUENCE ANALYSIS, DNA; VIRAL LOAD; YOUNG ADULT;

EID: 84873585378     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056170     Document Type: Article

References (28)

1. Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vezinet F, et al. (1998) Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel. JAMA 279: 1984-1991.
2. Bertagnolio S, Soto-Ramirez L, Pilon R, Rodriguez R, Viveros M, et al. (2007) HIV-1 drug resistance surveillance using dried whole blood spots. Antivir Ther 12: 107-113.
3. Johannessen A, Holberg-Petersen M, Lovgaarden G, Naman E, Ormaasen V, et al. (2010) HIV type-1 drug resistance testing on dried blood spots is feasible and reliable in patients who fail antiretroviral therapy in rural Tanzania. Antivir Ther 15: 1003-1009.
4. Ji H, Li Y, Graham M, Liang BB, Pilon R, et al. (2011) Next-generation sequencing of dried blood spot specimens: a novel approach to HIV drug-resistance surveillance. Antivir Ther 16: 871-878.
5. UNAIDS (2010) AIDS epidemic update-December 2009.
6. Novitsky V, Lagakos S, Herzig M, Bonney C, Kebaabetswe L, et al. (2009) Evolution of proviral gp120 over the first year of HIV-1 subtype C infection. Virology 383: 47-59.
7. Josefsson L, King MS, Makitalo B, Brannstrom J, Shao W, et al. (2011) Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc Natl Acad Sci U S A 108: 11199-11204.
8. Bi X, Gatanaga H, Ida S, Tsuchiya K, Matsuoka-Aizawa S, et al. (2003) Emergence of protease inhibitor resistance-associated mutations in plasma HIV-1 precedes that in proviruses of peripheral blood mononuclear cells by more than a year. J Acquir Immune Defic Syndr 34: 1-6.
9. Masciotra S, Garrido C, Youngpairoj AS, McNulty A, Zahonero N, et al. (2007) High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. AIDS 21: 2503-2511.
10. Hallack R, Doherty LE, Wethers JA, Parker MM, (2008) Evaluation of dried blood spot specimens for HIV-1 drug-resistance testing using the Trugene((R)) HIV-1 genotyping assay. J Clin Virol 41: 283-287.
11. Ziemniak C, George-Agwu A, Moss WJ, Ray SC, Persaud D, (2006) A sensitive genotyping assay for detection of drug resistance mutations in reverse transcriptase of HIV-1 subtypes B and C in samples stored as dried blood spots or frozen RNA extracts. J Virol Methods 136: 238-247.
12. Kroodsma KL, Kozal MJ, Hamed KA, Winters MA, Merigan TC, (1994) Detection of drug resistance mutations in the human immunodeficiency virus type 1 (HIV-1) pol gene: differences in semen and blood HIV-1 RNA and proviral DNA. J Infect Dis 170: 1292-1295.
13. Steegen K, Luchters S, Demecheleer E, Dauwe K, Mandaliya K, et al. (2007) Feasibility of detecting human immunodeficiency virus type 1 drug resistance in DNA extracted from whole blood or dried blood spots. J Clin Microbiol 45: 3342-3351.
14. Vicenti I, Razzolini F, Saladini F, Romano L, Zazzi M, (2007) Use of peripheral blood DNA for genotype antiretroviral resistance testing in drug-naive HIV-infected subjects. Clin Infect Dis 44: 1657-1661.
15. Saracino A, Gianotti N, Marangi M, Cibelli DC, Galli A, et al. (2008) Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART. J Med Virol 80: 1695-1706.
16. Ji H, Masse N, Tyler S, Liang B, Li Y, et al. (2010) HIV drug resistance surveillance using pooled pyrosequencing. PLoS ONE 5: e9263.
17. Huse SM, Huber JA, Morrison HG, Sogin ML, Welch DM, (2007) Accuracy and quality of massively parallel DNA pyrosequencing. Genome Biol 8: R143.
18. Ji H, Li Y, Graham M, Liang B, Tyler S, et al. (2011) National HIV Drug Resistance surveillance using Tagged Pooled Pyrosequencing. The 18th Conference on Retrovirus and Opportunistic Infections. CROI 2011 Abstract 664.
19. WHO (2010) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach-2010 Revision.
20. Bertagnolio S, Parkin NT, Jordan M, Brooks J, Garcia-Lerma JG, (2010) Dried blood spots for HIV-1 drug resistance and viral load testing: A review of current knowledge and WHO efforts for global HIV drug resistance surveillance. AIDS Rev 12: 195-208.
21. Rottinghaus EK, Ugbena R, Diallo K, Bassey O, Azeez A, et al. (2012) Dried blood spot specimens are a suitable alternative sample type for HIV-1 viral load measurement and drug resistance genotyping in patients receiving first-line antiretroviral therapy. Clin Infect Dis 54: 1187-1195.
22. Monleau M, Montavon C, Laurent C, Segondy M, Montes B, et al. (2009) Evaluation of different RNA extraction methods and storage conditions of dried plasma or blood spots for human immunodeficiency virus type 1 RNA quantification and PCR amplification for drug resistance testing. J Clin Microbiol 47: 1107-1118.
23. Monleau M, Butel C, Delaporte E, Boillot F, Peeters M, (2010) Effect of storage conditions of dried plasma and blood spots on HIV-1 RNA quantification and PCR amplification for drug resistance genotyping. J Antimicrob Chemother 65: 1562-1566.
24. Steegen K, Luchters S, Demecheleer E, Dauwe K, Mandaliya K, et al. (2007) Feasibility of detecting human immunodeficiency virus type 1 drug resistance in DNA extracted from whole blood or dried blood spots. J Clin Microbiol 45: 3342-3351.
25. McNulty A, Jennings C, Bennett D, Fitzgibbon J, Bremer JW, et al. (2007) Evaluation of dried blood spots for human immunodeficiency virus type 1 drug resistance testing. J Clin Microbiol 45: 517-521.
26. Pierson TC, Zhou Y, Kieffer TL, Ruff CT, Buck C, et al. (2002) Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol 76: 8518-8531.
27. Masciotra S, Garrido C, Youngpairoj AS, McNulty A, Zahonero N, et al. (2007) High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. AIDS 21: 2503-2511.
28. Wei X, Youngpairoj AS, Garrido C, Zahonero N, Corral A, et al. (2011) Minority HIV mutation detection in dried blood spots indicates high specimen integrity and reveals hidden archived drug resistance. J Clin Virol 50: 148-152.